Compare Abbott Laboratories (ABT) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Intuitive Surgical, Inc. — how do they compare? Abbott Laboratories trades at $95.37 (market cap $166.94B), while Intuitive Surgical, Inc. trades at $418.56 (market cap $151.33B). The key difference: Abbott Laboratories and Intuitive Surgical, Inc. are close in size by market cap, and Abbott Laboratories pays a 2.63% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| ABT | ISRG | |
|---|---|---|
Market Cap | $166.94B | $151.33B |
Sector | Health | Health |
52-Week High | $136.62 | $592.85 |
52-Week Low | $82.57 | $397.68 |
Enterprise Value | $193.69B | $146.82B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Intuitive Surgical (ISRG) trades at $427.30, up 0.3% on the day, with a bullish technical outlook supported by moving averages and strong support at $422. The company reported robust Q1 2026 earnings of $2.50 per share, beating estimates, and has consistently exceeded expectations. Revenue grew to $10.06 billion in 2025, with a net income margin of 28.15%, though valuation multiples remain elevated with a P/E of 52.59.
The outlook is positive, driven by procedure growth guidance of 13.5-15.5% for 2026 and analyst consensus targeting $565.20. Risks include premium valuation sensitivity and reimbursement challenges in new markets like appendectomy. Institutional sentiment is bullish, with 69% of analysts rating it a buy, but investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
